Financial Analysis: Moolec Science (MLEC) vs. Its Rivals

Moolec Science (NASDAQ:MLEC) is one of 673 public companies in the “Holding & other investment offices” industry, but how does it weigh in compared to its rivals? We will compare Moolec Science to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Moolec Science and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	128	730	961	19	2.47

Moolec Science presently has a consensus price target of $6.00, suggesting a potential upside of 582.67%. As a group, “Holding & other investment offices” companies have a potential upside of 52.38%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Moolec Science is more favorable than its rivals.

Valuation & Earnings

This table compares Moolec Science and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.39
Moolec Science Competitors	$1.02 billion	$81.17 million	64.10

Moolec Science’s rivals have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 54.2% of shares of all “Holding & other investment offices” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by insiders. Comparatively, 26.7% of shares of all “Holding & other investment offices” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Moolec Science has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s rivals have a beta of 0.03, indicating that their average share price is 97% less volatile than the S&P 500.

Profitability

This table compares Moolec Science and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-97.95%	-27.91%
Moolec Science Competitors	-20.30%	-43.48%	-0.54%

Summary

Moolec Science rivals beat Moolec Science on 10 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.